Novo Nordisk A/S reported turnover of DKK 66.8 billion (€8.98 billion) in the first half, up by 5% from the previous year, lifted by sales of its glucagon-like peptide-1 (GLP-1) medicines for diabetes. The three medicines in this group, Rybelsus, Ozempic and Victoza, had sales of DKK 23.4 billion, or more than a third of total group revenue.
